GİRİŞ: Pleomorfik fibrom, ilk kez 1989 yılında Kamino ve ark. tarafından tanımlanan, nadir görülen benign fibröz bir deri tümörüdür. Çeşitli kutanöz bölgelerde bildirilmiş olmasına rağmen, erkek genital bölge yerleşimi daha önce tanımlanmamıştır. OLGU SUNUMU: Yirmi yedi yaşında erkek hasta, penis frenulumunda yavaş büyüyen ve ağrısız bir kitle ile başvurdu. Hastanın, cinsel uyarılma sırasında üretral akıntıyı önlemek amacıyla frenulum çevresine tekrarlayan şekilde bant uygulama öyküsü mevcuttu ve bu durum kronik mekanik iritasyona yol açmıştı. Lezyon spinal anestezi altında tamamen eksize edildi. Histopatolojik incelemede, nükleer atipi içermeyen pleomorfik fibroblast benzeri hücreler ve güçlü vimentin pozitifliği saptanarak pleomorfik fibrom tanısı doğrulandı. Altı aylık takipte nüks izlenmedi. TARTIŞMA: Pleomorfik fibrom, belirgin sitolojik pleomorfizme rağmen klinik olarak indolent seyirli nadir bir benign neoplazmdır. Genital tutulum son derece nadirdir ve sunulan olgu, penis yerleşimli ilk vaka niteliğindedir. Kronik mekanik mikrotravmanın fibroblastik proliferasyonu tetikleyerek patogenezde rol oynayabileceği düşünülmektedir. SONUÇ: Pleomorfik fibrom, özellikle kronik lokal travma öyküsü bulunan hastalarda penis kitlelerinin ayırıcı tanısında dikkate alınmalıdır. Cerrahi eksizyon küratif olup, nüks son derece nadirdir. Anahtar Kelimeler: pleomorfik fibroma, penis, benign tümör, kronik iritasyon
Objectives: To examine the association between the nerve‐sparing (NS) technique applied during radical prostatectomy (RP) and early oncological and continence outcomes in patients with Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)‐defined high‐risk prostate cancer (PCa) undergoing robot‐assisted RP (RARP) within a structured patient‐specific surgical planning (PSSP) pathway. Patients and Methods: A retrospective single‐centre cohort study of 1385 patients who underwent primary RARP between 2021 and 2022 was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Patients were stratified into three groups according to the number of STAMPEDE‐defined high‐risk factors: none, one, and two or more. Outcomes were compared across these cohorts and between NS‐ and non‐NS (nNS)‐ RARP, within each risk stratum. Results: Overall, NS‐RARP was performed in 75.4% of patients (1044/1385). In the STAMPEDE‐defined high‐risk cohort (two or more high‐risk criteria) 57.3% (150/262) of patients underwent some sort of NS. Among those with at least two STAMPEDE‐defined risk factors, oncological outcomes were similar between NS and nNS surgery (positive surgical margin rate 21.3% vs 23.2%, P = 0.72; 12‐month biochemical recurrence rate 6.7% vs 5.4%, P = 0.9), and urinary continence rates at 3 and 12 months were also similar ( P = 0.2 and P = 0.5, respectively). However, high‐risk patients undergoing NS‐RARP used significantly fewer pads at 12 months ( P = 0.03). Conclusion: In a contemporary RARP cohort within a PSSP pathway, NS was feasible in over half of high‐risk patients and was not associated with worse short‐term oncological outcomes. Although pad‐free continence rates were similar between NS and nNS groups, patients undergoing NS‐RARP used significantly fewer pads at 12 months, suggesting a potential functional benefit that warrants further prospective evaluation of NS strategies in selected cases.
Background/Objectives: Prostate cancer (PCa) incidence is rising, with radical prostatectomy (RP) as the main curative surgery for localised cases, which includes removing seminal vesicles (SV). SV invasion (SVI) predicts poor oncological outcomes, making accurate preoperative staging to identify SVI crucial for surgical planning. This ensures oncological safety by enabling wide excision when needed, while preserving tissue to maintain function. This review synthesises current evidence on pre-biopsy MRI findings and/or clinicopathological parameters to diagnose SVI in PCa. Methods: A literature search (2005–2025) using OVID for studies assessing pre-biopsy MRI findings, with a priori eligibility for clinicopathological or combined MRI–clinicopathological models (index tests), for detecting SVI (outcome) compared to RP histopathology (standard reference) in patients with primary localised PCa (patients). This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Risk of bias was evaluated with QUADAS-2, and pooled diagnostic accuracy metrics and study heterogeneity were analysed. Results: Five studies qualified, while three used binary mpMRI classification and were quantitatively analysed. No eligible studies assessed clinicopathological predictors or combined MRI–clinicopathological models; all included studies evaluated pre-biopsy MRI findings only, and none included high-dimensional radiomics. The pooled sensitivity was 0.66 (95% CI: 0.52–0.78), specificity 0.94 (0.89–0.97), positive predictive value (PPV) 0.76 (0.60–0.87), negative predictive value (NPV) 0.92 (0.85–0.94), and diagnostic odds ratio 30.13 (12.36–73.47), with moderate heterogeneity. All included studies were retrospective cohorts with considerable risk of bias. Conclusions: In the small number of heterogeneous, single-centre retrospective studies available, pre-biopsy MRI findings show high specificity and NPV for preoperative detection of SVI but only moderate sensitivity, which limits its reliability as a standalone tool. The pooled diagnostic accuracy estimates should be interpreted as exploratory. These findings should therefore be interpreted cautiously. Future studies must integrate MRI with clinicopathological data, addressing this key evidence gap before firm conclusions can be drawn or clinical practice changed.